Navigation Links
ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
Date:1/21/2017

REDWOOD CITY, Calif., Jan. 20, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, presented new Phase 1b clinical data on the Company's lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at the 2017 Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology (ASCO), taking place January 19-21, 2017 in San Francisco, CA.

"AM0010 induces the expansion of novel T cell clones and activated CD8+ T cells in the blood and tumors of our patients," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  "Our Phase 1b study in advanced pancreatic cancer patients evaluates the additive or synergistic anti-tumor function of AM0010 in combination with the FOLFOX chemotherapy regimen. We are excited to present for the first time the data from this study in which we achieved a 16% objective response rate, including 2 complete responses.  To advance our AM0010 program, we began enrolling patients in an international Phase 3 randomized pivotal clinical trial of AM0010 in combination with FOLFOX as second-line therapy for advanced metastatic pancreatic cancer."

In the Phase 1b clinical trial, 21 patients with advanced pancreatic cancer were treated with AM0010 in combination with FOLFOX.  The patients had previously progressed on a prior gemcitabine containing regimen and had a median number of two prior therapies (ranging from 1 to 5).  Fifteen of 19 (79%) patients who were evaluable for tumor responses had disease control according to the immune-related Response Criteria (irRC).  Three (16%) had objective responses, including 2 that achieved a complete response and 1 partial response.  The median progression free survival of all 21 treated patients was 3.5 months and the median overall survival has not been reached after a median follow-up of 10.5 months (3.8-15.6+ months). AM0010 in combination with FOLFOX has been well tolerated.

About AM0010 Poster Presentation at ASCO Gastrointestinal Cancers Symposium
Abstract Title: Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). (Abstract #399)
Lead Author: J. Randolph Hecht, M.D., Professor of Clinical Medicine and Director of the Gastrointestinal Oncology Program, David Geffen School of Medicine, UCLA
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date: Friday, January 20, 2017, 12:30-2:00 PM and 5:30-6:30 PM (Pacific Time)
Location: Level 1, West Hall (Board #J5)

About AM0010
AM0010 is a long-acting form of recombinant human IL-10, which has shown sustained anti-tumor effects and a good safety/tolerability profile in patients from multiple oncology indications. Due to its enhanced half-life, AM0010 has strong immune-stimulating effects that induce the activation, proliferation, and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in patients. CD8+ T cells mediate the tumor clearing effect of this immuno-oncology agent.

The U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted AM0010 Orphan Drug designation for the treatment of pancreatic cancer. The FDA also granted Fast Track designation for AM0010 in combination with FOLFOX as a second-line therapy in patients with pancreatic cancer.

ARMO is conducting an international Phase 3 randomized pivotal clinical trial with AM0010 for the treatment of pancreatic ductal adenocarcinoma (PDAC). In a Phase 1/1b clinical trial in 350 cancer patients across more than 14 different types of cancer, AM0010 demonstrated the ability to increase the number of activated CD8+ T cells in the blood and tumors of patients and achieve objective tumor responses, including partial and complete responses, in patients treated with AM0010 as a single agent or in combination with chemotherapeutic drugs or anti-PD-1 checkpoint inhibitors.

About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010, stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells.  CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.

In addition, ARMO is developing a robust immuno-oncology pipeline that includes validated product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies. For more information, please visit www.armobio.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/armo-biosciences-presents-new-phase-1b-clinical-data-for-am0010-in-advanced-pancreatic-cancer-patients-at-2017-gastrointestinal-cancers-symposium-300394226.html


'/>"/>
SOURCE ARMO BioSciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences Provides Portfolio Update
2. Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies
3. Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
4. Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
5. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of Pancreatic Cancer
6. Drug Makers Stocks Under Scanner -- Novo Nordisk, Synergy Pharma, Pernix Therapeutics, and Apricus Biosciences
7. Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting
8. Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
9. Arkis BioSciences Closes $3.4 Million Series-A Investment
10. Leading BioSciences Appoints Greg Doyle as Chief Executive Officer
11. Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):